NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Regenxbio Inc. RGNX
13 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$170.4M
▲ 104.5% vs FY2024
EPS · FY25
$-3.76
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-107.0%
Net margin · FY25
-113.8%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 170.4M
Revenue, FY2025 · full 13-year series below
Revenue
Net income
The company lost 114 cents on every revenue dollar this year.
Per share
USD -3.76
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-107.0%
Return on equity, FY2025
ROE
Operating margin-94.6%
Net margin-113.8%
Return on assets-42.2%
Each USD of equity lost 107 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+2.0% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+14.8%
+2.0%
+36.5%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.05B
Shares outstanding, FY2025
Change, 5 years+35.8%
Change, 10 years+93.4%
The share count grew 36% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 453.0M
total assets, end of FY2025
Total assetsUSD 453.0M
EquityUSD 102.7M
CashUSD 34.5M
Current ratio2.38×
Equity funds 23% of total assets.
History
13 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Revenue $B
0.2
0.1
0.1
0.1
0.5
0.2
0.0
0.2
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.2
−0.2
−0.3
−0.3
0.2
−0.1
−0.1
0.1
−0.1
−0.1
−0.0
−0.0
−0.0
EBITDA $B
·
·
·
·
·
·
·
·
·
·
·
·
·
Income tax $B
0.0
0.0
−0.0
−0.0
0.0
0.0
−0.0
0.0
0.0
−0.0
0.0
0.0
0.0
Net income $B
−0.2
−0.2
−0.3
−0.3
0.1
−0.1
−0.1
0.1
−0.1
−0.1
−0.0
−0.0
−0.0
EPS, diluted $
−3.76
−4.59
−6.02
−6.50
2.91
−2.98
−2.58
2.73
−2.45
−2.38
−2.59
−1.82
−2.50
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−107.0
−79.5
−63.7
−43.8
22.4
−26.9
−19.8
28.9
−42.4
−33.3
−23.0
·
·
Shares out B
0.05
0.05
0.04
0.04
0.04
0.04
0.04
0.04
0.03
0.03
0.03
0.00
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
37 of 37
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed